Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study
Key Points
Key points are not available for this paper at this time.
Abstract
Vosoritide treatment has safe and persistent growth-promoting effects in children with achondroplasia treated daily for two years.
AI에게 질문
Like
Bookmark
Share
View Full Paper
AI에게 질문
Like
Bookmark
Share
View Full Paper
Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study | Synapse